Dupilumab in patients with bullous pemphigoid and concomitant atopy
Dupilumab appears to be a safe and highly effective treatment for patients with concurrent BP and AD, leading to rapid and sustained symptom control, resolution of skin lesions, and high patient satisfaction.
Authors
- Stefan Beissert (ORCID: https://orcid.org/0000-0002-8327-8475)
- Stephan R. Künzel (ORCID: https://orcid.org/0000-0001-6302-1755)
- Susanne Abraham (ORCID: https://orcid.org/0000-0001-7457-6481)
- Katerina Jobst
Institutions
- DRK-Blutspendedienst Baden-Württemberg - Hessen (DE)
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fphar.2025.1656089
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00